6.31
6.31 (0%)
As of Apr 17, 2025
Pulmatrix, Inc. [PULM]
Source:
Company Overview
Pulmatrix, Inc. is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using our patented iSPERSE™ technology.
| Country | United States |
| Headquarters | bedford, massachusetts |
| Phone Number | (781) 357-2333 |
| Industry | manufacturing |
| CEO | Teofilo Raad |
| Website | www.pulmatrix.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $7.8 |
| Operating Profit | $-9.8 |
| Net Income | $-9.6 |
| Net Cash | $-11.1 |
Profit Ratios
| Gross Margin | $7.8 |
| Operating Margin | -125.1 |
| Profit as % of Revenues | -81.7% |
| Profit as % of Assets | -43.6% |
| Profit as % of Stockholder Equity | -106.8% |
Management Effectiveness
| Return on Equity | -106.8% |
| Return on Assets | -96.1% |
| Turnover Ratio | 35.6% |
| EBITA | $-9.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $9.9 |
| Total Liabilities | $1 |
| Operating Cash Flow | $-10.7 |
| Investing Cash Flow | $-0.4 |
| Financing Cash Flow | $0 |
